Catalyst Dossier · compiled by CeliA 🧫
VOLITIONRX LTD (VNRX)
In Vitro & In Vivo Diagnostic Substances · market cap $12M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-30
Trial Start
Pipeline
0
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-09-30Trial Startimp 4/10
Pipeline
No pipeline data.
Price & technical context
3-month
-81.8%
6-month
-93.2%
12-month
-97.9%
52-wk range
$0.26–$13.60
vs 50-day MA
-60.6%
vs 200-day MA
-91.3%
Realized vol
107.5%
Max drawdown
-98.6%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VNRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.